^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    golidocitinib (DZD4205)

    i
    Other names: DZD4205, AZD-4205, AZD 4205, AZD4205, DZD-4205
    Company:
    Dizal Pharma
    Drug class:
    JAK1 inhibitor
    Related drugs:
    5d
    PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL (clinicaltrials.gov)
    P2, N=47, Recruiting, Ruijin Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Epidaza (chidamide) • golidocitinib (DZD4205)
    8d
    Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26). (PubMed, Blood Cancer J)
    No TRAEs leading to fatal outcomes were reported. This study suggests the potential of golidocitinib as maintenance therapy for patients with PTCL.
    P2 data • Journal
    |
    JAK1 (Janus Kinase 1)
    |
    golidocitinib (DZD4205)
    26d
    JACKPOT38: Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC (clinicaltrials.gov)
    P2, N=20, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    golidocitinib (DZD4205)
    1m
    Case Report: Targeting the Achilles' heel of monomorphic epitheliotropic intestinal T-cell lymphoma. (PubMed, Front Oncol)
    We report the case of a 34-year-old female with refractory MEITL who failed prior lines of therapy, including CHOPE and gemcitabine/oxaliplatin (GemOx) combined with golidocitinib. Future efforts should focus on optimizing combination partners for venetoclax to improve efficacy and tolerability. The rationale for exploring venetoclax as post-transplant maintenance therapy in MEITL is also discussed.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • gemcitabine • oxaliplatin • golidocitinib (DZD4205)
    1m
    T-START-M1: Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy: A Multicenter, Randomized, Double-Blind, Phase III Clinical Trial (clinicaltrials.gov)
    P3, N=68, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
    New P3 trial
    |
    ALK negative
    |
    golidocitinib (DZD4205)
    2ms
    PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL (clinicaltrials.gov)
    P2, N=47, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    Epidaza (chidamide) • golidocitinib (DZD4205)
    2ms
    Golidocitinib Combined With Selinexor for CAEBVD (clinicaltrials.gov)
    P2/3, N=28, Recruiting, Beijing Friendship Hospital
    New P2/3 trial
    |
    Xpovio (selinexor) • golidocitinib (DZD4205)
    2ms
    Serum free fatty acid promotes tumor progression and predicts golidocitinib sensitivity in peripheral T-cell lymphoma. (PubMed, Blood Adv)
    In alignment with our experimental findings, relapsed or refractory PTCL patients with high serum FFA exhibited superior responses to golidocitinib treatment than those with low serum FFA. Collectively, high serum FFA is related to tumor progression and indicates golidocitinib sensitivity, providing novel insights into reprogramming lipid metabolism to dually target the tumor and microenvironment in PTCL.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • IL6 (Interleukin 6) • IL10 (Interleukin 10)
    |
    ALK positive • ALK negative
    |
    golidocitinib (DZD4205)
    2ms
    Prospective Single-Arm Clinical Trial of GO Regimen for HLH. (clinicaltrials.gov)
    P2/3, N=28, Recruiting, Beijing Friendship Hospital
    New P2/3 trial
    |
    golidocitinib (DZD4205)
    2ms
    EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas (clinicaltrials.gov)
    P1/2, N=60, Not yet recruiting, Sun Yat-sen University
    New P1/2 trial
    |
    Epidaza (chidamide) • zeprumetostat (SHR-2554) • golidocitinib (DZD4205)
    3ms
    Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=101, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Epidaza (chidamide) • golidocitinib (DZD4205) • Duoenda (mitoxantrone liposomal)
    3ms
    A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21) (clinicaltrials.gov)
    P2, N=90, Recruiting, Dizal Pharmaceuticals | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Zegfrovy (sunvozertinib) • golidocitinib (DZD4205)